Hydrocortisone liquid - Eton Pharmaceuticals
Alternative Names: ET-400; ET-800; Hydrocortisone vial; KHINDIVILatest Information Update: 01 Sep 2025
At a glance
- Originator Crossject
- Developer Eton Pharmaceuticals
- Class Alcohols; Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Adrenal insufficiency
Most Recent Events
- 07 Aug 2025 Eton Pharmaceuticals expects supplement new drug application (sNDA) approval for Hydrocortisone liquid before the end of 2026
- 07 Aug 2025 Eton Pharmaceuticals expects to file a supplement new drug application (sNDA) for Hydrocortisone liquid in the first half of 2026
- 07 Aug 2025 Eton Pharmaceuticals plans a pre-submission meeting with the FDA in September 2025